# Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

> **NCT00061958** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Adenocarcinoma of the Esophagus
- Stage III Esophageal Cancer
- Stage IV Esophageal Cancer

## Interventions

- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00061958
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2005-04
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061958, "Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00061958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*